NEW YORK, Oct. 24 - Xenon Genetics, a privately held Canadian genomics firm, has acquired the lipid metabolism drug-discovery program of QuantaNova Canada, Xenon said on Wednesday. 

The acquisition, which includes a portfolio of novel genes and proprietary screening and diagnostic assays, is intended to help Xenon develop therapeutics for diabetes, obesity, and cardiovascular disease, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.